Journal article icon

Journal article

Sodium valproate: who knew what and when? Cumulative meta-analysis gives extra insights

Abstract:

Sodium valproate is licensed in the EU for treating generalized, partial, or other forms of epilepsy. It has also been used to treat bipolar disorder and to prevent migraine. In February of this year, the European Medicines Agency recommended that sodium valproate should not be used during pregnancy unless no other effective treatment is available, and that it must not be used in women able to have children, unless the conditions of a pregnancy prevention programme are met.[1] These measures ...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1136/bmjebm-2018-111068

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Primary Care Health Sciences
Oxford college:
Kellogg College
Role:
Author
ORCID:
0000-0002-1009-1992
More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
Primary Care Health Sciences
Role:
Author
Publisher:
BMJ Publishing Group
Journal:
Evidence-Based Medicine More from this journal
Volume:
24
Issue:
4
Pages:
127-129
Publication date:
2018-10-22
Acceptance date:
2018-08-14
DOI:
EISSN:
1473-6810
ISSN:
1356-5524
Pmid:
30348656
Language:
English
Keywords:
Pubs id:
pubs:934713
UUID:
uuid:d016b3c9-2fe1-4a9b-a37e-0260957bda1b
Local pid:
pubs:934713
Source identifiers:
934713
Deposit date:
2018-11-08

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP